Royalty Pharma plc Class A Ordinary Shares
Market Cap
24B
Short interest (May 15)
2.9%
Net Short (Jun 03 ): -0.2%
Borrow Fee
0.35%
↑ 8.1%
Available Shares
7M
↓ 14.3%
Price Chart
Company Overview
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.